imiquimod has been researched along with Pneumonia, Viral in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Farsalinos, K; Poulas, K; Zanidis, C | 1 |
| Alexandris, N; Angelopoulou, A; Farsalinos, K; Konstantinou, E; Mesiakaris, K; Poulas, K; Zanidis, C | 1 |
2 other study(ies) available for imiquimod and Pneumonia, Viral
| Article | Year |
|---|---|
Activation of TLR7 and Innate Immunity as an Efficient Method Against COVID-19 Pandemic: Imiquimod as a Potential Therapy.
Topics: Adjuvants, Immunologic; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Imiquimod; Immunity, Innate; Pandemics; Pneumonia, Viral; SARS-CoV-2; Toll-Like Receptor 7 | 2020 |
Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19.
Topics: Adaptive Immunity; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokines; Humans; Imiquimod; Immunity, Innate; Pandemics; Pneumonia, Viral; SARS-CoV-2; Toll-Like Receptor 7 | 2020 |